Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3672 | Sofusa DoseConnect Wiki | 1.00 |
| drug687 | CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc Wiki | 1.00 |
| drug2933 | Placebo Administration Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001172 | Arthritis, Rheumatoid NIH | 0.27 |
| D001168 | Arthritis NIH | 0.23 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001370 | Rheumatoid arthritis HPO | 0.27 |
| HP:0001369 | Arthritis HPO | 0.23 |
Navigate: Correlations HPO
There is one clinical trial.
This is an open-label pilot study in patients with rheumatoid arthritis (RA). All patients will receive SOFUSA Enbrel 25 mg once weekly. The dose will be increased to 50 mg if the dose escalation criteria are met during the dose escalation phase of the study.
Description: Incidence and severity of adverse events and their relationships to SOFUSA administration
Measure: Incidence and severity of adverse events and their relationships to SOFUSA administration Time: Baseline through Week 12Description: Change from Baseline in DAS28(CRP) score at Week 12
Measure: Change in Disease Activity Score 28-joint count C reactive protein (DAS28(CRP)) Time: Baseline to Week 12Description: Change from Baseline in DAS28(CRP) score over time
Measure: Change in DAS28(CRP) score over time Time: Baseline through Week 12Description: Change from Baseline in DAS28(ESR) score over time
Measure: Change in Disease Activity Score 28-joint count erythrocyte sedimentation rate (DAS28(ESR)) over time Time: Baseline through Week 12Description: Change from Baseline in SDAI score over time
Measure: Change in Simplified Disease Activity Index (SDAI) score over time Time: Baseline through Week 12Description: Change from Baseline in CDAI score over time
Measure: Change in Clinical Disease Activity Index (CDAI) score over time Time: Baseline through Week 12Description: Proportion of patients with DAS28(CRP) score < 2.9 over time
Measure: Proportion of patients with low disease activity (LDA) over time as assessed by the DAS28(CRP) Time: Baseline through Week 12Description: Proportion of patients with DAS28(ESR) score ≤ 3.2 over time
Measure: Proportion of patients with LDA over time as assessed by the DAS28(ESR) Time: Baseline through Week 12Description: Proportion of patients with SDAI score ≤ 11.0 over time
Measure: Proportion of patients with LDA over time as assessed by the SDAI Time: Baseline through Week 12Description: Proportion of patients with CDAI score ≤ 10 over time
Measure: Proportion of patients with LDA over time as assessed by the CDAI Time: Baseline through Week 12Description: Proportion of patients achieving ACR20/50/70 response over time
Measure: Proportion of patients achieving ACR20/50/70 response over time Time: Baseline through Week 12Description: Proportion of patients achieving moderate or good EULAR response over time
Measure: Proportion of patients achieving moderate or good EULAR response over time Time: Baseline through Week 12Description: Proportion of patients achieving a MCID of 0.22 in HAQ-DI over time
Measure: Proportion of patients achieving a minimally clinically important difference (MCID) of 0.22 in the Health Assessment Questionnaire-Disability Index (HAQ-DI) over time Time: Baseline through Week 12Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports